These biomarkers were selected in part due to the reagent availability, but also, with the exception of CEA, because they represented some of the more novel lung cancer markers identified, with few studies indicating elevated expression in the circulation of patients with early stage disease [24]. The gene discussed is CEACAM5; the disease is lung carcinoma.